



The  
Patent  
Office

PCT/EP 98 / 0 6 2 7 8

EP 98 / 0 6 2 7 8  
0 9 / 5 2 9 0 5 0

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP9 1RH

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D	13 NOV 1998
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*Andrew Gersey*

Dated

18 SEP 1998

# The Patent Office

Patent Form 1/77 - 001030  
1/7700 05.70 - 770117 7

# 1/77

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your Reference	GL/PU3375	07 OCT 1997
2. Patent application number (The Patent office will fill in this part)	9721139.5	
3. Full name, address and postcode of the or of each applicant (underline all surnames)	GLAXO GROUP LIMITED GLAXO WELLCOME HOUSE BERKELEY AVENUE GREENFORD MIDDLESEX UB6 ONN GB  Patents ADP number (if you know it)  If the applicant is a corporate body, give the country/state of its corporation	
	00473587003	<div style="border: 1px solid black; padding: 5px; text-align: center;">           THE PATENT OFFICE            D            07 OCT 1997            RECEIVED BY POST         </div>
4. Title of the invention	MEDICAMENTS	
5. Name of your agent (if you know one)	GRAHAM M H LANE (SEE CONTINUATION SHEET)	
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	GLAXO WELLCOME PLC GLAXO WELLCOME HOUSE, BERKELEY AVENUE GREENFORD, MIDDLESEX UB6 ONN, GB	
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)  Date of Filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES	

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	12
Description	15
Claim(s)	1
Abstract	-
Drawing(s)	-

10. If you are also filing any of the following, state how many against each item

Priority Documents


Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patent Form 9/77)

Request for substantive examination (Patent Form 10/77)

Any other documents (please specify)



11. I/We request the grant of a patent on the basis of this application

*Graham M H Lane*

Signature GRAHAM M H LANE  
AGENT FOR THE APPLICANTS

6 October, 1997

12. Name and daytime telephone number of person to contact in the United Kingdom  
SARAH DOE  
0181-966 5721

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office.

**Additional Agents**  
**(See Page 1 No. 5)**

**NAME(S)**

Alan HESKETH  
Laurence David JENKINS  
Karen CRAWLEY  
William Michael DADSON  
Peter I. DOLTON  
Hugh B. DAWSON  
Wendy Anne FILLER  
Alison GALLAFENT  
Ruth Elizabeth HACKETT  
Catriona McLeod HAMMER  
Audrey G. C. HAMMETT  
Graham M.H. LANE  
Stephanie Anne LEAROYD  
Helen Kaye QUILLIN  
Michael A. REED  
Marion REES  
Michael John STOTT  
Andrew J. TEUTEN  
Rachel M. THORNLEY  
Janis Florence VOLCKMAN

**ADDRESS**

Glaxo Wellcome plc  
Glaxo Wellcome House  
Berkeley Avenue  
Greenford  
Middlesex  
UB6 ONN  
Great Britain


## MEDICAMENTS

The invention relates to a new medical use for compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT<sub>3</sub> receptors.

5-HT<sub>3</sub> receptor antagonists may be identified by methods well known in the art, for example by their ability to inhibit 3-(5-methyl-1H-imidazole-4-yl)-1-[1-[<sup>3</sup>H]-methyl-1H-indol-3-yl]-1-propanone binding in rat entorhinal cortex homogenates (following the general procedure described by G Kilpatrick *et al*, Nature, 1987, 330, 746-748), and/or by their effect on the 5-HT-induced Bezold-Jarisch (B-J) reflex in the cat (following the general method described by A Butler *et al*, Br. J. Pharmacol., 94, 397-412 (1988)).

A number of different 5-HT<sub>3</sub> receptor antagonists have been disclosed, for example those of group A: granisetron, talipexole, azasetron, tropisetron, mirtazapine, ramosetron, ondansetron, lerisetron, alosetron, N-3389, zacopride, cilansetron, E-3620, lintopride, KAE-393, itasetron, mosapride and dolasetron.

In UK Patent No. 2209335, incorporated herein by reference, there is disclosed, *inter alia*, the compound 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, now known as alosetron, which may be represented by the formula (I):



and pharmaceutically acceptable salts, solvates and pharmaceutically acceptable equivalents thereof, in particular its hydrochloride salt.

5-HT<sub>3</sub> receptor antagonists are known to be useful in the treatment of a variety of conditions involving 5-HT<sub>3</sub> receptor-mediated mechanisms, including in particular emesis.

Irritable bowel syndrome (IBS) is the most common diagnosis made by gastroenterologists (1) and is characterised by abdominal pain and discomfort

and altered bowel functions (2-4). To date, no laboratory or structural defects have been identified in IBS and the formal diagnosis is based upon a constellation of symptoms defined by either the Manning (5) or Rome Criteria (6).

5 The current understanding of the pathophysiology or aetiology of IBS is limited, and no proven effective therapy is available (3,7). Moreover, many patients gain slight or even no relief from such therapies. Thus, there is a real need to develop new medicines for the treatment of IBS.

10 Over the last two decades compelling evidence has accumulated that a state of enhanced perception of visceral stimuli develops in patients with IBS (2,3,8-10). In balloon distension studies of the colon or rectum the threshold for sensation of pain is lower in IBS patients compared to controls, and this has been proposed as a biological marker for IBS (11). In view of the evidence for enhanced visceral perception in IBS and the frequent occurrence of pain, any agent considered to be of utility in the treatment of IBS should demonstrate effectiveness in the relief of pain.

20 Of the classes of therapeutic agents which have been proposed for the treatment of abdominal pain in IBS, 5-HT<sub>3</sub>-receptor antagonists are among the most promising. In animal models, these agents have been shown to decrease visceral pain responses (12,13). Furthermore, the 5-HT<sub>3</sub>-receptor antagonist, ondansetron, has been shown to slow colonic transit in normal volunteers (14-15). In patients with IBS ondansetron increases rectal compliance (16) and in diarrhoea-predominant IBS patients ondansetron improves stool consistency (17-19). Ondansetron also inhibits the contractile response of the colon in healthy volunteers in the early postprandial period (20), the time when many IBS patients experience symptoms. A second 5-HT<sub>3</sub>-receptor antagonist, granisetron, has also been shown to produce a decrease in rectal sensitivity, and reduce post-prandial motor activity in IBS patients (21).

30 Alosetron is a potent and selective 5-HT<sub>3</sub>-receptor antagonist, and in preliminary reports, alosetron has been shown to improve abdominal pain (22), and to slow colonic transit in IBS patients (23).

Surprisingly, it has now been found that 5-HT<sub>3</sub> receptor antagonists represent a particularly effective and well tolerated therapy in nonconstipated female IBS patients.

5 According to one aspect the invention therefore provides a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of nonconstipated female IBS.

10 By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt or solvate of a 5-HT<sub>3</sub> receptor antagonist or any other compound, which upon administration to the recipient is capable of providing (directly or indirectly) a 5-HT<sub>3</sub> receptor antagonist or an active metabolite or residue thereof.

In one preferred aspect the invention provides a compound of Group A or a pharmaceutically acceptable derivative thereof for use in the treatment of nonconstipated female IBS.

15 In a further preferred aspect the invention therefore provides alosetron or a pharmaceutically acceptable derivative thereof for use in the treatment of nonconstipated female IBS.

20 Suitable pharmaceutically acceptable salts of alosetron include acid addition salts formed with inorganic or organic acids (for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p-toluenesulphonates, methanesulphonates, sulphamates, ascorbates, tartrates, salicylates, succinates, lactates, glutarates, glutaconates, acetates, tricarballates, citrates, fumarates and maleates), and solvates (for example hydrates) thereof.

25 In a preferred embodiment of the present invention alosetron is employed in the form of its hydrochloride.

In another aspect, the invention provides the use of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of nonconstipated female IBS.

Within the above aspects and preferred aspects of the invention, the use of a 5-HT<sub>3</sub> receptor antagonist of Group A, more preferably alosetron, is especially preferred.

5 It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.

10 Conveniently, a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients. Thus a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof may, for example, be formulated for oral, sub-lingual, buccal, parenteral, rectal or intranasal administration, or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose), or in a form suitable for topical administration.

15 For oral administration the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrates (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and 25 preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). 30

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.



It will be appreciated that the precise therapeutic dose of a 5-HT<sub>3</sub> receptor antagonist, expressed in the form of its free base, will depend on the age and condition of the patient and the nature of the IBS to be treated, and will be at the ultimate discretion of the attendant physician.

5 However, in general, effective doses for the treatment of nonconstipated female IBS patients will lie in the range of 0.001 to 500mg, such as 0.01 to 100mg, preferably 0.05 to 50mg, for example 0.5 to 25mg per unit dose, which could be administered in single or divided doses, for example, 1 to 4 times per day.

10 In a preferred embodiment, effective doses of alosetron for the treatment of nonconstipated female IBS patients will lie in the range of 0.01 to 100mg, such as 0.05 to 50mg, preferably 0.1 to 25mg, for example 0.5, 1, 2 or 4mg of alosetron per unit dose, which could be administered in single or divided doses, for example, 1 to 4 times per day.

15 The use of alosetron in the treatment of nonconstipated female IBS patients is supported by the following clinical data.

#### Patients

20 Three hundred and seventy IBS patients were randomised for study: 80 were randomised to treatment with placebo BID, 72 to 1 mg BID alosetron, 74 to 2 mg BID alosetron, 76 to 4 mg BID alosetron and 68 to 8 mg BID alosetron. Table 1 shows the demographic characteristics for patients in all 5 treatment groups, and characteristics were similar between treatment arms. Patients were required to have symptoms which fulfilled the Rome Criteria for IBS (5) for at least 6 months. Because of the ability of 5-HT<sub>3</sub>-receptor antagonists to slow colonic transit (14-15), constipation-predominant IBS patients were excluded from this study, and only patients with diarrhoea-predominant IBS or alternating constipation/diarrhoea were included.

#### Study Design

30 Daily and weekly symptom data were collected using a recently described electronic touch-tone telephone based system (24,25). Patients underwent a 2 week screening period with no IBS treatment to ensure sufficient baseline level of abdominal pain as well as compliance with the data collection system. Pain

5 For parenteral administration the compositions may take the form of injections, conveniently intravenous, intramuscular or subcutaneous injections, for example bolus injections or continuous intravenous infusions. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, optionally with an added preservative.

10 The compositions for parenteral administration may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the compositions may be in dry form such as a powder, crystalline or freeze-dried solid for constitution with a suitable vehicle, e.g. sterile pyrogen-free water or isotonic saline before use. They may be presented, for example, in sterile ampoules or vials.

For rectal administration the compositions may take the form of suppositories or retention enemas.

15 Tablets for sub-lingual administration may be formulated in a conventional manner.

For intranasal administration, or administration by inhalation or insufflation, conventional formulations may be employed.

20 For topical administration the pharmaceutical compositions may be liquids, for example solutions, suspensions or emulsions presented in the form of creams or gels.

25 In addition to the formulations described previously, the compositions may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously, transcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Daily stool consistency scores and daily number of bowel movements were averaged over the baseline, weekly for weeks 1-4, and monthly (weeks 1-4, 5-8, and 9-12) intervals. In addition, the proportion of days patients experienced a sense of urgency was calculated over the monthly and weekly intervals. For the monthly intervals, the treatment groups were compared for change from baseline using a van Elteren test adjusted for investigator cluster. For the weekly intervals, the treatment groups were compared at each week using a van Elteren test adjusted for investigator cluster.

#### Adequate Relief of Pain and Discomfort

<u>% Responders</u>	<u>Alosetron (mg BID)</u>				
	Placebo	1	2	4	8
FEMALE	33	60	59	51	52
MALE	53	20	50	54	52

Examination of each dose of alosetron showed a greater proportion of female responders for adequate relief as compared with placebo. The largest treatment effect occurred with 1 mg BID alosetron where 27% more responders were observed as compared to that seen with placebo (33% placebo vs 60% alosetron;  $p=0.013$ ). A similar result was observed with 2 mg BID alosetron where 59% responders were seen ( $p=0.026$ ). No meaningful improvement relative to placebo was seen in the male population with any dose of alosetron. However, the placebo response in males was substantially greater than that seen in females.

was assessed daily on a 5 point scale (0=none; 1=mild; 2=moderate; 3=intense; 4=severe). Average baseline pain over the 2 week screening period was required to be between 1.5-3.3, inclusive, and at least 4 days with at least moderate pain was required for enrolment into the study. Stool consistency data were also collected (1=very hard; 2=hard; 3=formed; 4=loose; and 5=watery). During the screening period an average stool consistency score of  $\geq 2.5$  was required for entry into the study in order to exclude those with predominant constipation.

Following the screening period, eligible patients were randomised with equal allocation to 12 weeks of study medication (BID) of placebo or alosetron 1, 2, 4 or 8 mg taken prior to meals. Patients were followed for 2 weeks post-treatment. During the screening period, treatment phase and follow-up period, patients were asked daily questions about their IBS symptoms. Once every 7 days, during the treatment phase of the study, patients responded to an additional question as to whether they had obtained adequate relief of their IBS-related abdominal pain and discomfort during the previous 7 days.

### Statistics

For this study, a responder was prospectively defined as a patient who completed the treatment phase of the study and reported adequate relief of their IBS pain and discomfort for at least 6 weeks. Responders for adequate relief have been shown to display a strong correlation with improvement in abdominal pain, bowel function and quality of life as compared to nonresponders (26). In addition, a monthly responder was defined as a patient who reported adequate relief of their IBS pain and discomfort for at least 2 weeks per month. For the monthly analysis, a last observation carried forward procedure was employed, whereby a month with all missing weeks was assigned the number of weeks with adequate relief from the previous non-missing month. Thus, this analysis satisfied the Intent-to-Treat principle by including all patients and months. Treatment groups were compared for the proportion of patients defined as responders, for both endpoints, using a Mantel-Haenszel test stratified for investigator cluster. Finally, the proportion of weeks with adequate relief was compared between treatment groups using a log-rank test.

Improvement in Bowel Habits

5 In females patients, most doses of alosetron significantly improved stool consistency, bowel movement frequency and the proportion of days with urgency as compared to placebo (Table 2). For each of these parameters, a statistically significant benefit over placebo was achieved after 1 week of treatment and benefit persisted throughout the remainder of the 12 week treatment period. Among males, no significant improvement over placebo was seen in the bowel-related functions with the exception of stool consistency. Stool consistency in males improved significantly with doses of alosetron higher than 1 mg BID.

10 These results demonstrate that alosetron significantly improved abdominal pain and bowel function in female IBS patients. Alosetron also significantly improved, in female patients, three clinically relevant bowel related functions: number of bowel movements per day, stool consistency, and sense of urgency. All of these parameters were significantly improved within the first week of treatment and were sustained throughout the three month study.

15 Surprisingly, alosetron-mediated improvement in the efficacy parameters, with the exception of hardening in stool consistency, were found to occur only in females.

20 Based upon the results of the present study, alosetron appears to represent an effective and well tolerated therapy in nonconstipated female IBS patients.

<u>% Weeks with adequate relief</u>	<u>Alosetron (mg BID)</u>				
	Placebo	1	2	4	8
FEMALE	33	58	50	50	50

5 The proportion of weeks with adequate relief was also evaluated. Placebo treated female patients had a median 33% of weeks with adequate relief. With 1 mg BID alosetron, female patients reported adequate relief for a median 58% of the weeks ( $p=0.039$ ). In the treatment groups receiving greater than 1 mg alosetron (i.e., 2 mg, 4 mg and 8 mg BID) female patients reported having adequate relief for a median 50% of the weeks with each of the doses of alosetron. By contrast, male patients received no meaningful benefit with respect to the proportion of weeks with adequate relief with alosetron.

<u>% Responders</u>	<u>Monthly Intervals</u>		
	1	2	3
Placebo	32	42	36
Alosetron 1mg BID	53	62	60

10 In order to identify how rapidly alosetron produces adequate relief, we analysed adequate relief during each of the three months of the study. With 1 mg BID alosetron, statistically significant improvement occurred for female patients during each month. Increases of 21%, 20% and 24% above placebo were seen at months 1, 2 and 3, respectively. Alosetron 1 mg was superior to the other alosetron (2, 4, or 8 mg) evaluated. No improvement relative to placebo was  
15 seen among males at any month, with any dose of alosetron.

Table 2

Effects of Alosetron on Bowel Function In Female Patients With IBS

		Alosetron BID			
<u>Function</u>	<u>Placebo</u>	<u>1 mg</u>	<u>2 mg</u>	<u>4 mg</u>	<u>8 mg</u>
(n)	(59)	(53)	(51)	(55)	(40)
% Days with Urgency	54.3 ± 32.04	33.0 ± 28.8*	35.9 ± 34.4**	37.8 ± 34.2*	41.5 ± 33.6
Stool # per day	2.2 ± 1.35	1.4 ± 1.0 *	1.7 ± 0.9 *	1.8 ± 1.2 *	1.3 ± 0.7 *
Stool Consistency	2.9 ± 0.69	2.1 ± 0.83**	2.2 ± 0.73**	2.4 ± 0.74**	1.8 ± 0.64**

mean ± SD

Data collected from week 9-12 interval

p-values are based on change from baseline

\*  $p \leq 0.01$  with respect to placebo\*\*  $p \leq 0.001$  with respect to placebo

Consistency score: 1=very hard, 2=hard, 3=formed, 4=loose, 5=watery

Table 1  
Demographic Characteristics

Characteristic n	Placebo 80	Alosetron BID			
		1mg 72	2mg 74	4mg 76	8mg 68
Age (yrs)	43.3 + 14.9	44.7 + 13.5	43.9 + 14.9	44.3 + 11.9	45.1 + 14.8
Sex					
Male	21 (26%)	19 (26%)	23 (31%)	21 (28%)	28 (41%)
Female	59 (74%)	53 (74%)	51 (69%)	55 (72%)	40 (59%)
Race					
Caucasian	76 (95%)	67 (93%)	67 (91%)	75 (99%)	63 (93%)
Black	3 (4%)	3 (4%)	4 (5%)	0 (0%)	0 (0%)
Other	1 (1%)	2 (3%)	3 (4%)	1 (1%)	5 (6%)
Females					
Post-Menopausal	10 (17%)	9 (17%)	9 (18%)	9 (16%)	8 (20%)
Sterile	25 (42%)	29 (55%)	25 (49%)	35 (64%)	19 (48%)
Child-bearing Potential	24 (41%)	15 (28%)	17 (33%)	11 (20%)	13 (33%)
Duration of IBS Symptoms (yrs)	9.8 + 10.9	10.3 + 10.4	9.4 + 9.9	9.9 + 9.3	9.3 + 7.7
Baseline Pain	2.23 + 0.47	2.12 + 0.48	2.11 + 0.42	2.22 + 0.48	2.30 + 0.47

Pain score: 0=none, 1=mild, 2=moderate, 3=intense, 4=severe



References

1. Everhart JJ, Renault PF. Irritable bowel syndrome in office-based practice in the United States. *Gastroenterology* 1991; 100:998-1005.
2. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. *Gastroenterology* 1994; 107:271-93.
3. Camilleri M, Choi M-G. Review article: irritable bowel syndrome. *Aliment. Pharm. Ther.* 1997; 11:3-15.
4. Drossman DA. Chronic functional abdominal pain. *Am. J. Gastroent.* 1996; 91:2270-81.
5. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards a positive diagnosis of the irritable bowel. *Br. Med. J.* 1978; 2:653-4.
6. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. *Gastroent. Int.* 1989; 2:92-5.
7. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. *Gastroenterology* 1988; 95:232-41.
8. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. *Gut* 1973; 14:125-132.
9. Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, Schuster MM. Tolerance for rectosigmoid distension in irritable bowel syndrome. *Gastroenterology* 1990; 98:1187-92.
10. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. *Gastroenterology* 1997; 112:1714-43.
11. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. *Gastroenterology* 1995; 109:40-52.

12. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. *Br. J. Pharm.* 1990; 100:497-501.
- 5 13. Scott CM, Grundy D, Boissonade F, Bountra C. Alosetron inhibits the colorectal distension-evoked depressor response and spinal c-fos expression in the anesthetized rat. *Gastroenterology* 1997; 112:A822.
- 10 14. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. *Aliment. Pharm. Ther.* 1990; 4:139-44.
- 15 15. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomet C, Zinsmeister AR, MacCarty RL, Ciociola A. GR 38032F (ondansetron), a selective 5-HT<sub>3</sub> receptor antagonist, slows colonic transit in healthy man. *Dig. Dis. Sci.* 1990; 35:477-80.
- 16 16. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. *Dig. Dis. Sci.* 1995; 40:819-27.
- 20 17. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. *Mayo Clinic Proc.* 1992; 67:732-8.
- 25 18. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? *Aliment. Pharm. Ther.* 1996; 10:595-9.
19. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JRM, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT<sub>3</sub> antagonism (ondansetron). *Digestion* 1996; 57:478-83.
20. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. *Gut* 1994; 35:536-41.

The application of which this specification and claim form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features relating to the invention described herein. They may take the form of product, process or use claims and may include, by way of example and without limitation, the following claim:

#### Claims

1. Use of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of nonconstipated female IBS.

2. Use according to claim 1 wherein the 5-HT<sub>3</sub> receptor antagonist is alosetron or a pharmaceutically acceptable derivative.

3. Use according to claim 2 wherein alosetron is in the form of its hydrochloride.

4. Use according to claim 1 wherein the 5-HT<sub>3</sub> receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, or dolasetron.

5. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof.

6. A 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of nonconstipated female IBS.

21. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT<sub>3</sub> -receptor antagonist, in patients with irritable bowel syndrome. *Aliment. Pharm. Ther.* 1993; 7:175-80.
- 5 22. Bardhan K, Bodemar G, Geldof H, Schutz E, Snell C, Darekar B. A double-blind, placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. *Gastroenterology* 1996; 110:A630.
23. Forster JM, Houghton LA, Whorwell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome. *Gastroenterology* 1997; 112: A732.
- 10 24. Harding J, Reynolds L, Sorrells S, Haw J, Mangel A, Webb D, Northcutt A. A novel electronic data collection system for symptoms in IBS. *Gastroenterology* 1997; 112:A745.
- 15 25. Harding JP, Hamm LR, Ehsanullah RSB, Heath AT, Sorrells SC, Haw J, Dukes GE, Wolfe SG, Mangel AW, Northcutt AR. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. *Aliment. Pharm. Ther.* 1997. In Press.
26. Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GD, McSorley D. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. *Aliment. Pharm. Ther.* 1997; Submitted.